Multinational EBRT Data Support Curative-Intent Role in Early HCC : J Clin Oncol | May 2026

Introduction

External Beam Radiation Therapy has historically played a limited role in the management of Hepatocellular Carcinoma because of concerns regarding hepatic toxicity and limited survival data. However, advances in stereotactic body radiation therapy, image guidance and conformal radiation planning have substantially improved the safety and precision of liver-directed radiotherapy. Despite growing incorporation of EBRT into international guidelines, robust multinational survival data comparable to surgery or ablation have remained limited.

Problem Statement

The absence of large individual patient-level datasets has hindered accurate assessment of long-term survival outcomes following EBRT in HCC. Whether EBRT can provide outcomes comparable to established curative-intent therapies such as resection or thermal ablation—particularly in early-stage disease—has remained controversial.

Summary

This multinational individual patient data analysis evaluated outcomes in nearly 5,000 patients with HCC treated using EBRT across multiple international centers, representing the largest collaborative dataset reported to date. Survival outcomes were stratified according to Barcelona Clinic Liver Cancer (BCLC) stage and prior treatment status. Patients with very early-stage and early-stage disease demonstrated particularly favorable outcomes. Median overall survival reached 6.8 years in BCLC-0 disease and 4.6 years in BCLC-A disease. Among treatment-naïve patients, survival outcomes were even more impressive, with median overall survival not reached in BCLC-0 patients and exceeding five years in BCLC-A disease.

Multivariable analysis identified established prognostic factors associated with mortality, including advanced BCLC stage, greater tumor burden, impaired performance status and poorer liver function. Importantly, delivery of ablative radiation doses and more contemporary treatment eras were independently associated with improved survival, highlighting the impact of modern radiation techniques and evolving patient selection strategies.

The study provides compelling evidence that modern EBRT can achieve long-term survival outcomes in very early and early-stage HCC that appear comparable to established curative locoregional therapies including resection and thermal ablation. These findings are particularly relevant for patients unsuitable for surgery or ablation because of tumor location, vascular proximity, comorbidity or impaired hepatic reserve.

Overall, this landmark multinational analysis strengthens the evidence base supporting EBRT as a legitimate curative-intent treatment modality in selected patients with early-stage HCC. The findings further reinforce the integration of EBRT into contemporary BCLC treatment algorithms and multidisciplinary HCC decision-making pathways.